Objectives: FDA accelerated approvals for some chemotherapies used PFS as an OS surrogate. However, one mBC approval was revoked after OS gains were not observed post-approval. We compared PFS with OS by first-line (1L) chemotherapy using real world evidence from US mBC patients. MethOds: IMS Health Comprehensive Disease Records for Breast Cancer link IMS PharMetrics Plus, oncology EMRs, and Social Security Death Index. Female breast cancer patients 233.0) were selected with index metastasis x or EMR Stage IV) 7/1/ 2006-3/31/2012 or new cytotoxic agents [NCA]), enrollment 180 days pre-index and ≥ 30 days post-index, and no other malignancies. PFS proxy was 1L duration; OS was measured until death or censoring (end of enrollment). Log-rank analysis compared PFS by 1L treatment. A Cox proportional hazards model assessed post-1L OS by 1L chemotherapy and duration, propensity for NCA vs. AT, HER2 status, and patient characteristics. Results: Of 845 mBC patients, 334 met study criteria (mean [SD] age= 51.7 [8.7] years, 20.4% HER2+). Propensity for NCA (n= 70) vs. AT (n= 264) increased with diabetes history (OR= 2.79, 95% CI 1.12-6.90) and higher pre-index health care expenditures (OR= 1.27, 95% CI 1.05-1.54). 1L NCAs were administered a mean (median) 195.2 (73.0) days (anthracyclines 53.5 [44.0], taxanes 122.2 [47.5], -2Log LR 54.3, 2 df, p< .0001)
Objectives: FDA accelerated approvals for some chemotherapies used PFS as an OS surrogate. However, one mBC approval was revoked after OS gains were not observed post-approval. We compared PFS with OS by first-line (1L) chemotherapy using real world evidence from US mBC patients. MethOds: IMS Health Comprehensive Disease Records for Breast Cancer link IMS PharMetrics Plus, oncology EMRs, and Social Security Death Index. Female breast cancer patients 233.0) were selected with index metastasis x or EMR Stage IV) 7/1/ 2006 -3/31/2012 or new cytotoxic agents [NCA] ), enrollment 180 days pre-index and ≥ 30 days post-index, and no other malignancies. PFS proxy was 1L duration; OS was measured until death or censoring (end of enrollment). Log-rank analysis compared PFS by 1L treatment. A Cox proportional hazards model assessed post-1L OS by 1L chemotherapy and duration, propensity for NCA vs. AT, HER2 status, and patient characteristics. Results: Of 845 mBC patients, 334 met study criteria (mean [SD] age= 51.7 [8.7] years, 20.4% HER2+). Propensity for NCA (n= 70) vs. AT (n= 264) increased with diabetes history (OR= 2.79, 95% CI 1.12-6.90) and higher pre-index health care expenditures (OR= 1.27, 95% CI 1.05-1.54). 1L NCAs were administered a mean (median) 195.2 (73.0) days (anthracyclines 53.5 [44.0], taxanes 122.2 [47.5] , -2Log LR 54.3, 2 df, p< .0001). Cox regression estimated that 30 additional days of 1L chemotherapy predicted slightly shorter post-1L OS (HR= 1.03, 95% CI 1.00-1.06); NCA (vs. AT) predicted stronger decreases in post-1L OS (HR= 2.32, 95% CI 1.11-4.86) despite propensity adjustment. cOnclusiOns: Duration of 1L chemotherapy, as a proxy for PFS, predicted slightly shorter post-1L OS. Choice of 1L chemotherapy was a stronger predictor of post-1L OS, adjusted for selection bias. Real world data suggests that PFS is a poor OS surrogate in mBC.
PCN11 magNitude oF BeNeFit aNd Costs FoR ReCeNt solid tumoR ageNts
Binder G. 1 , Milentijevic D. 2 , Squier M. 1 , Whiting S. 1 , Brown G. , Renschler M. F. 1 1 Celgene Corporation, Summit, NJ, USA, 2 Market Access Solutions, Raritan, NJ, USA Objectives: Phase 3 oncology clinical trials have had success rates of 41% (Djulbegovic, Arch Int Med 2008) . Against this backdrop, context is needed on the magnitude of benefit to expect from future successful trials, and the interplay of cost. Recognizing the limitations of comparing results across trials and therapies, we assessed recent FDA solid tumor approvals showing overall survival (OS) benefit in a randomized trial. The objective of this analysis is to define the magnitude of benefit and cost of solid tumor therapies approved by FDA from 2009-2013 having phase 3 OS benefit. MethOds: A systematic review of CenterWatch FDA-Approved Drugs and FDA sNDA/sBLA databases was conducted. Inclusion criteria required FDA approval or efficacy supplement, with OS data published 2009-2013. Hazard ratio (HR) and absolute and relative gain in median OS were assessed. First month drug costs were determined for 4Q2013, using methods previously described by Bach (NEJM 2009) . Agents intended to be administered for £ 6 weeks were excluded from the cost analysis. Limitations include omission of many agents that represent important advances yet did not demonstrate statistically significant OS benefit relative to a control arm. Results: 18 FDA approved agents across 25 indications for 9 tumor types were assessed. The mean HR (range) and the mean relative gain in median OS vs trial comparator was 0.702 (0.410-0.817) and 27.91% (11.9%-67.2%), respectively. Medians for each measure were 0.725 and 23.6%. Mean first month treatment costs were $12,601 ($5,881-$50,025) with median costs of $9,282. cOnclusiOns: Over the last 5 years, for FDA-approved agents for treatment of solid tumors, the magnitude of survival benefit, measured either as Hazard Ratio or relative gain in median OS, was 24-30%. This benefit, and first month costs of $9 -13,000, may represent midpoints of expected levels for future solid tumor agents. HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, USA, 4 Mckesson Specialty Health, Fairfax, VA, USA, 5 Mckesson Specialty Health, The Woodlands, TX, USA, 6 Bayer HealthCare Pharmaceuticals, Inc., White House Station, NJ, USA Objectives: To describe and characterize mCRC patients who received 3 rd -line therapy and to investigate the association of patient outcomes and treatment patterns in a real-world community oncology network. MethOds: This retrospective study utilized data from the iKnowMed™ database and billing claims. Eligibility criteria included diagnosis of mCRC, initiation of 1 st -line therapy between 1/1/2007 and 6/30/2011, and initiation of 3 rd -line therapy (defined as index date) before 6/30/2012. The key outcome was overall survival (OS). Kaplan-Meier and Cox proportional hazard models were used to characterize the distribution and predictors of outcomes. Results: 757 patients were eligible for the study. The most common 3 rd -line therapies were anti-EGFR-based (55.4%), oxaliplatin-based (13.6%), and capecitabinebased (11.4%). OS was 8.0 (95% CI: 7.1-8.9), 8.8 (7.4-11.0), and 9.1 (6.9-11.2) months, respectively. Over half of patients were ≤ 65 years old (54.3%), male (55.2%), treated in the Southern region (61.8%), overweight/obese (56.6%), and the majority had an ECOG performance status ≤ 1 (78.7%). 51.8% of patients had prior comorbidities. The 5 most common comorbidities were hematologic, cardiovascular, gastrointestinal, neurologic, and endocrine disease. KRAS testing rates at index date were 35.4% (wild-type 26.3%, mutation 9.1%). Of KRASwild-type patients, 80.9% were treated with anti-EGFRbased regimens which was consistent with NCCN recommendations. cOnclusiOns: This comparative effectiveness study in a real-world community setting shows that PCN7 aN aNalysis oF BiomaRkeR testiNg aNd aPPRoPRiate tReatmeNt amoNg womeN with BReast CaNCeR usiNg oNCology emR data Objectives: Personalized treatment for biomarker-specific breast cancer is a reality. However, outcomes research has lagged behind due to lack of data sources capturing testing, results, and drug treatment. This study uses a new oncology electronic medical record (EMR) database to examine testing, documentation of results, and appropriate treatment among a cohort of women with breast cancer treated in community oncology practices. MethOds: The Truven Health MarketScan® Oncology EMR Database was used to select patients diagnosed with breast cancer between July 1, 2011 and September 30, 2013 who had at least 2 visits and known disease stage. Biomarker tests and results for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) were observed along with patients' drug treatment. Results: 57,660 women met inclusion criteria. Documented biomarker testing varied by disease stage and test. ER testing was > 90% for women with stage I or II; 77% for stage IV patients. More than 86% of women with stage 0-III and 71% with stage IV had a PR test. HER2 testing was documented in 66% with stage 0, 77% with stage I-III, and 63% with stage IV. Overall, 74%, 55%, and 2% of women who were ER positive, HER2 positive, and HER2 negative respectively received biomarker specific treatment. Treatment rates varied by disease stage, with > 80% of stage IV women receiving appropriate treatment for ER positive or HER2 positive cancer. Among HER2 negative stage IV women, appropriate treatment was 16%. 6%, 12%, and 14% of patients respectively had a biomarker result that was not consistent with ER positive, HER2 positive, and HER2 negative treatment received. cOnclusiOns: Documentation of appropriate testing varied both by the type of test and disease stage. Quality improvement programs aimed at documentation as well as appropriate treatment may benefit patients treated in community oncology practice.
PCN12 tReatmeNt PatteRNs aNd outComes iN metastatiC ColoReCtal CaNCeR (mCRC) PatieNts tReated iN a CommuNity oNCology settiNg

PCN8 is dePRessioN Related to uNdeRuse oF BReast CaNCeR sCReeNiNg?
Park C. , Ma X. , Lawson K. A. The University of Texas at Austin, Austin, TX, USA
Objectives: Many studies have demonstrated that depression is associated with poor adherence to treatment of various diseases. Previous research has shown inconsistent results regarding the impact of depression on mammography use behaviors. The objective of this study was to assess the relationship between women's depression and mammography use. To MethOds: This cross-sectional study used data from the 2012 Behavioral Risk Factor Surveillance System (BRFSS) and employed the Health Belief Model (HBM). The independent variable was the presence of depression. The dependent variable was mammogram use, which was defined based on the U.S. Preventive Services Task Force's mammogram guidelines, categorized at three levels: 1) had never been screened, 2) had been screened, but not within two years, and 3) had been screened within two years. Multivariate ordinal logistic regressions were used for analyses. Results: An estimated population size of 45,578,030 women was included. Among this population, 23.02% of women reported the presence of a depressive disorder. A chi-square test showed a significant relationship between mammogram use and depression (p< 0.001). The unadjusted proportional odds ratio [95% CI] when comparing women with depression to women without depression on mammogram use was 0.81 [0.76, 0.86], which means that both the odds of 'screened within two years' versus the combined 'screened, but not within two years' and 'never screened' and the odds of combined 'screened within two years' and 'screened, but not within two years' versus 'never screened' were 0.81 times lower for women with depression when compared to women without depression (p< 0.001). However, when demographic and HBM characteristics were held constant in the regression model, the adjusted proportional odds ratio [95% CI] (1.05 [0.97, 1.14]) was not significant (p= 0.197). cOnclusiOns: Depression itself was related to the underuse of mammography. However, after controlling for demographic and HBM characteristics, depression was not associated with the underuse of mammography. Blavatska O. Danylo Halytskyj Lviv National Medical University, Lviv, Ukraine Objectives: Screening of colon, stomach, bladder, prostate cancers is very relevant to reduce mortality. The applicable diagnosis scheme doesn't allow detecting tumor processes in the early stages, later diagnosis increases cost of the next treatment, reducing its effectiveness and declines the length and quality of life. MethOds: We proposed to improve diagnostics of colorectal and stomach cancer using one test; to apply the test for occult blood for urological field. Application of a combined test for determining hidden "high" and "low" bleeding in both fields displays this type of screening in a very interesting and economically appropriate rank. Rapid test for occult blood specific for human hemoglobin and transferrin is more sensitive, freely available in the pharmacy network, economically priced, easy to use and gives results on "cito". Results: The first year results of the test use data are analyzed. Patients used tests purchased at their own expense. We've tested 88 patients for diagnosing possible colorectal and stomach cancer and 182 urological patients for diagnosing possible cancer of bladder and prostate. All 88 digestive patients test results for diagnosing possible colorectal and stomach cancer were negative; among 182 tests of the urological patients we received 17 positive results, future diagnostics proved 7 Cr-cases and 1 with precancerous (is under control). Such data does not allow yet statistic analysis. cOnclusiOns: The project is under implementation. For 7 Cr-diagnosed patients the treatment allows almost twice increase of expected life time and the 8-th patient may become our first preventive Cr-case. Proved efficiency of the screening algorithm would become a basis for changing the national standard of medical care in Lviv region and Ukraine in general. however, median overall survival (OS) analyses do not adequately capture this type of prolonged survival effect. Therefore, additional value metrics are necessary to completely describe ipilimumab's survival impact in treatment-naïve metastatic melanoma patients vs other anti-cancer agents. MethOds: We conducted a literature review of trial data supporting approval of agents for various metastatic cancers within the last 10 years. Metrics included primary/secondary OS, median OS at approval, and Kaplan-Meier (KM) survival curves. Each agent was plotted, with x-axis reflecting total drug cost and y-axis reflecting improvement vs comparator for median and mean OS (area under KM curve), 1-year survival, and 1-year number needed to treat (NNT) to avoid 1 death. A line indicating an average cost-to-benefit ratio identified agents with highest relative value per metric. Ipilimumab (3-mg/ kg monotherapy) pooled phase II/III data from chemotherapy-naïve patients were assessed within this value metric portfolio. Results: Ipilimumab demonstrated high relative median OS improvement vs comparator (48.4% [0.3%-63.3% with other agents]), the greatest absolute and relative mean OS improvements (6.9 months [0.2-6.4 months with other agents]; 60.1% [1.3%-34.3% with other agents]), the greatest relative 1-year survival improvement amongst first-line agents (41.9% [4.2%-38% with other agents]), and the lowest NNT (5 patients [6-66 with other agents]). Ipilimumab's high relative value was confirmed when plotting each drug's clinical performance vs total drug costs. cOnclusiOns: Using relevant survival metrics, ipilimumab demonstrates high relative value within a value metric portfolio in metastatic diseases. Long-term survival data for other agents for metastatic cancers are not yet available to estimate ipilimumab's long-term relative value.
PCN9
ComPlex sCReeNiNg test FoR eaRly CaNCeR diagNostiCs
PCN16 a ComPaRisoN oF toxiCity aNd suPPoRtive CaRe use BetweeN FouR CytotoxiC ageNts used iN the maNagemeNt oF metastatiC BReast CaNCeR (mBC))
Dranitsaris G. 1 , Knoth R. L. 2 , Cox D. 2 , Faria C. 2 1 Augmentium Pharma Consulting, Toronto, ON, Canada, 2 Eisai, Inc., Woodcliff Lake, NJ, USA Objectives: Capecitabine (C), gemcitabine (G) and vinorelbine (V) are commonly used as single agents in patients with MBC. Eribulin (E) is among the most recent cytotoxic agents to gain regulatory approval for MBC in the United States (U.S.) as a single agent. In this analysis, toxicity and supportive care use was compared between the four agents in a sample of MBC patients treated in a U.S. community oncology setting. MethOds: 411 patients (C= 144, G= 181, V= 96 and E= 90) who were treated in 19 community oncology clinics over the preceding two year period were identified. Data collection included baseline patient and disease characteristics, duration of therapy, supportive care, type of dose limiting toxicities and their impact on overall health care resource use. Results: The proportion of patients reporting at least one adverse event (any grade) with C, G, V and E was 45%, 65%, 75% and 63%. The most common toxicities with C, G and V were diarrhea (19.4%), anemia (34.6%) and neutropenia (50.0%). The most common toxicity for E was neutropenia (32.2%). Overall, 5.6%, 19.8%, 22.9% and 22.2% of patients receiving C, G, V and E required at least one medical intervention to manage a toxic event. Blood transfusions were most prevalent with G (12.3%) and V (13.5%). In contrast, unplanned clinic visits were most common with E (7.8%) and C (2.1%). Colony stimulating factor support was significantly higher with V (100%) relative to E (84.4%), G (72.9%) and C (63.9%) respectively (p < 0.01). However, toxicity was the cause of treatment discontinuation in significantly more patients receiving C (25.7%) compared to 8.6%, 11.5% and 8.9% of G, V and E patients (p < 0.05). cOnclusiOns: Significantly more patients receiving V required support with high cost colony stimulating factors. Capecitabine had less neutropenia and anemia, but more treatment discontinuations due to toxicity.
PCN17
RoBot-assisted veRsus CoNveNtioNal laPaRosCoPiC suRgeRy FoR ReCtal CaNCeR: a systematiC Review
Kim J. , Lee S. H. , Lim S. , Lee N. R. National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea Objectives: The aim of this systematic literature review is to evaluate the safety and effectiveness of robot-assisted surgery (RAS) and conventional laparoscopic rectal surgery (CLS) for rectal cancer. MethOds: We performed a systematic review of available literature. Three international databases (OvidMedline, Ovid EMBASE, Cochrane Central Rgister of Controlled Trials) and six Korean databases were used in searching for existing literature. The PICO and the search strategy were determined through consultation with a methodologist and a clinician. 1,664 studies were found at first. The final selection was made after removing duplicates and applying the inclusion and exclusion criteria established beforehand. The Cochrane Risk of Bias (RoB) was used for randomized clinical trial and the Methodological index for non-randomized (MINORS) for observational (cohort and case-control) studies were utilized for evaluating the quality of literature. Results: 15 two-arms studies involving 1,876 patients were finally included. RAS was associated with a lower rate of intraoperative conversion than CLS (RR= 0.29, 95% CI= 0.15-0.56). The operating time was higher for RAS (MD= 43.14, .02, I2= 95%), but only the directional nature could be determined due to the heterogeneity of literature. The RAS had a higher number of lymph node extraction (MD= 0.88, 95% CI= 0.00-1.75) and the time to first flatus was short (MD= 0.14, 95% CI= -0.28-0.00). However, this difference does not indicate a significant clinical difference. cOnclusiOns: RAS was associated with a lower intraoperative conversion rate than CLS, with no differences in complication rate as surrogate markers of successful surgery. although a variety of options were available on the market for 3 rd -line mCRC treatments, there is no conclusive evidence for an optimal choice in therapy. The difference in OS among chemotherapy backbones was not significant (log-rank test, p= 0.06), whether they were targeted therapies or not. Novel and newly approved treatments may provide further benefit for mCRC patients continuing on 3 rd -line therapy. Creteil, France, 2 MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, 3 LASER Analytica, Loerrach, Germany, 4 Hôpital du Cluzeau Centre Hospitalier Universitaire (CHU) de Limoges, Limoges, France, 5 Istituto Europeo di Oncologia, Rome, Italy, 6 Medical Oncology Unit, Department of Translational Oncology, Hospital Universitario La Paz, Madrid, Spain, 7 Université catholique de Louvain, Louvain, Belgium, Basel, Switzerland Objectives: In recent years, the treatment landscape in nsNSCLC has changed; new therapies (e.g. bevacizumab (BEV) indicated in 1L) have become available and other therapies (e.g. pemetrexed (PEM) in 1L and 2L) moved into earlier lines in the treatment paradigm. While there has been an expansion of the available treatment options, it is unclear how the therapy sequence rank in terms of best PFS for patients with nsNSCLC. MethOds: A therapy sequencing disease model that approximates treatment outcomes in up to five lines of treatment was developed for patients with nsNSCLC. The primary source of data for PFS and time to death was published pivotal trial data. All patients were treatment-naïve and in the PFS state, receive first-line treatment with either BEV-based therapy or doublet chemotherapy (including the option of pemetrexed + cisplatin (PEM+CIS)). Patients would then progress to a subsequent line therapy, remain in PFS or die. In case of progression, it was assumed that each survivor would receive a subsequent line of therapy (based on EMA licensed therapies). Weibull distribution curves were fitted to the data. Results: All BEV-based first-line therapy sequences analyzed achieved total PFS of more than 15 months. Bevacizumab-carboplatin-paclitaxel (1L) à pemetrexed (2L) à erlotinib (3L) à docetaxel (4L) resulted in total mean PFS time of 15.5 months, for instance. Sequences including PEM+CIS in first-line achieved total PFS times between 12.3 and 13.3 months with potentially (slightly) higher total PFS time achieved when assuming PEM continuation therapy in maintenance after PEM+CIS in 1L induction. cOnclusiOns: The model suggests that treatment sequencing strategies starting with a BEV-based combination in 1L yield better PFS outcomes than those starting with PEM-based combinations due to the possibility of one further-line treatment starting with BEV-based combination.
PCN18
Real-woRld saFety aNd eFFiCaCy oF NAB-PaClitaxel iN PatieNts with metastatiC BReast CaNCeR (mBC) tReated iN the uNited states: Results FRom a health iNsuRaNCe dataBase
PCN13 simulatioN aNd ComPaRisoN oF
PCN14 a PhaRmaCoeCoNomiC aPPRaisal oF CaBazitaxel veRsus aBiRateRoNe FoR the seCoNd-liNe tReatmeNt oF PatieNts with metastatiC hoRmoNe-ReFRaCtoRy PRostate CaNCeR (mhRPC) PRogRessiNg aFteR the tReatmeNt with doCetaxel: a systematiC Review
Bektur C. , Nurgozhin T.
Nazarbayev University, The Center for Life Sciences, Astana, Kazakhstan
Objectives: Currently,there are two drugs recommended by EAU for the secondline treatment of mHRPC after docetaxel-based therapy:cabazitaxel and abiraterone acetate. The purpose of this study was to evaluate the available data on effectiveness, safety and major pharmacoeconomic aspects of cabazitaxel and abiraterone for the treatment of patients with mHRPC progressing after the treatment with docetaxel. MethOds: Relevant publications were identified using a predefined search strategy on major academic databases (MEDLINE, EMBASE, Cochrane Library) and conference proceedings. Articles and documents published in English and Russian languages between January2010 and December2013 were accepted for the full text evaluation. Data(study characteristics and end points/results) was extracted and summarized from eligible articles accepted according to the applied inclusion and exclusion criteria. Results: 63 articles were accepted for the full text evaluation from 331 identified abstracts from primary search of databases. 17 full-text publications were included in the data extraction after meeting the predefined criteria. 59% of these publications were regarding the effectiveness and safety of drugs. The abiraterone treatment resulted in a higher median overall survival (15, 8 months, 95% CI, 14, (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) 0) than the therapy with cabazitaxel (15,1 months, 95% CI, 14,1-16,3). Moreover, median progression-free survival (median time to PSA progression) was 8.5 (95% CI 8,3-11,1) and 2.8 (95% CI 2,4-3,0) months, respectively. Overall, abiraterone has a better toxicity profile than cabazitaxel, the most common grade 3-4 adverse effects for abiraterone was fatigue(9%) and anaemia(8%), and for cabazitaxel they were neutropenia(82%) and diarrhea(6%). Abiraterone was more cost-effective compared to placebo ($94 -123.4K/QALY) than cabazitaxel compared to placebo ($149 -163.2K/QALY), according to 4 identified articles with CEA. cOnclusiOns: The results of present review show that abiraterone is a more favourable option for the second-line treatment of patients with mHRPC progressing after the docetaxelbased treatment than cabazitaxel in terms of safety and cost-effectiveness.
PCN15 the Relative CliNiCal aNd eCoNomiC value oF iPilimumaB as FiRst-liNe tReatmeNt oF metastatiC melaNoma veRsus otheR aNti-CaNCeR ageNts FoR metastatiC diseases
Abernethy A. P. 1 , Kotapati S. 2 , Gilloteau I. 2 , Karweit J. 3 , Wolfe S. 3 1 Duke University Medical Center, Durham, NC, USA, Princeton, NJ, USA, 3 IMS Consulting Group, New York, NY, USA Objectives: Payers, patients, and clinical decision-makers expect value from innovative anti-cancer agents. Ipilimumab, an anti-CTLA-4 monoclonal antibody, has been shown to provide durable long-term survival for a proportion of unresectable/metastatic melanoma patients, with follow-up in some out to 10 years;
